General |
Decreases bioavailability |
Generally removed |
Major factor in bioavailability; can take place in small intestine, liver and colon; usually to glucuronides but also sulphation and methylation [39]; facilitates urinary and biliary excretion [39]. |
Influence availability; catabolize compounds to low molecular weight compounds that are readily absorbed [58]. |
Flavan-3-ols (monomeric) |
|
|
Major bioactive forms: conjugates of epicatechin [41]; catechin: methyl, sulfate and glucuronic acid conjugates; epicatechin: mainly to sulfate conjugates, no glucuronidation [41]. |
|
Proanthocyanidins |
Decreases bioavailability [40]. |
|
Major bioactive forms: conjugates of epicatechin [41]; oligomeric procyanidins can absorb in small intestine [51]. |
Influences polymeric proanthocyanidin degradation [50]. |
Flavonols |
|
Sugars and their position affects bioavailability [44]. |
Potentially active metabolites: glucuronides [44]. |
Facilitates glucuronidation [60]. |
Anthocyanins |
Anthocyanin derivatives (flavan-3-ol-anthocyanin dimer) can potentially be absorbed with less efficiency [47]. |
Sometimes found with sugars intact in circulation [55]. |
Major intestinal metabolites: glucuronide and sulfate conjugates of protocatechuic acid and phloroglucinaldehyde [46]; anthocyanin derivatives metabolically more resistant than parent compounds [47]. |
|
Isoflavones |
|
Aglycone more bioavailable; possible deglycosylation prior hepatic metabolism [48]. |
|
Metabolize daidzein to equol [58]. |
Flavanones |
|
Rapid absorption, low bioavailability [49]. |
|
Extensive first-pass metabolism partly by intestinal bacteria degraded into phenolic compounds [49]. |